p53 immunocytochemistry and TP53 gene mutations in patients with chronic hepatitis C virus (HCV) infection. by Kasprzak, Aldona et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(1): 35 (35-42) 
doi: 10.2478/v10042-009-0003-5
Introduction
Chronic infection with hepatitis C virus (HCV) is
regarded as a risk factor for hepatocellular carcinoma
(HCC), mostly in patients with liver cirrhosis [1].
There are also evidences for the association of HCV,
mostly genotype 1b, with HCC without the interme-
diate step of cirrhosis [2-4]. The liver cell lines con-
stitutively expressing full-length or truncated ver-
sions of the HCV genome show a high incidence of
chromosome instability [5]. The potential candidates
for the group of oncogenes in development of HCC
include at least three HCV proteins, i.a., the core 
(C protein, capsid protein), NS3 and NS5A [6]. p53
gene (TP53) is considered the prototype tumor sup-
pressor gene and is the most extensively studied
tumour suppressor implicated in HCC [7]. Testing of
the gene status represents worldwide one of method
of diagnosing and establishing prognosis in HCC
[4,7-11]. Wild type TP53 codes for a nuclear phos-
phoprotein, which controls proliferation of normal
cells, DNA repair and apoptosis [12,13]. The protein
coded by TP53 manifests a short half-life and is
expressed in very small amounts, precluding the
chance to detect it using immunocytochemical tech-
niques [14]. Control of TP53 takes place also by the
alternative splicing while an additional protein prod-
uct (p47) controls ubiquitination, degradation, and
cell localization of p53 [15]. In neoplastic cells aug-
mented concentration of p53 protein is detected,
absent from normal cells [12]. Mutant p53 proteins are
easily detectable by immunocytochemical methods due
to their abnormally extended half-life [16]. The mutated
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p53 protein of an abnormal function may be responsible
for selective expansion of hepatocytes in the process of
cancerogenesis [17]. Frequency of TP53 mutations in
human HCC varies in geographic zones between 10%
and 60% of the cases [18-22]. Mutations of TP53 are
reported most frequently in countries with high risk of
HCC development, including China and South Africa, in
which they are linked to exposure to aflatoxin B1
(AFB1) and viral infections (mainly with hepatitis B
virus, HBV) [8,23-25]. In the countries most mutations
are at one nucleotide pair (Arg→Ser) of codon 249
[23,26,27]. A dramatic multiplicative effect on HCC risk
was demonstrated for a combined exposure to HBV and
249SER p53 mutations [28]. In countries of a low expo-
sure to AFB1 (Japan, European countries), the most fre-
quently described defects of TP53 in HCC involve point
mutations [19,29,30]. Loss of heterozygosity (LOH)
[29] and individual gene deletions were also reported
[30]. A common polymorphism at codon 72 resulting in
the change of arginine to proline has recently been cor-
related to HCC [22]. Most of investigators are of the
opinion that genetic alterations in TP53 are related to
rather late stages of hepatocellular carcinogenesis, which
are common for various etiologies of chronic hepatitis
[29,31]. Few reports only indicate that overexpression of
p53 and mutations of TP53 may manifest themselves
also in non-neoplastic hepatic lesions [26,32-34], and
upon exposure to AFB1 presence of 249SER TP53 muta-
tion is also detected [35]. Still no ideal molecular mark-
er of various HCC developmental stages is available for
epidemiological and diagnostic studies even if suitability
is stressed of plasma tests for the presence of TP53 muta-
tions, including quantitative studies (qSOMA) [9,11].
In view of the scanty number of studies on the role
of p53 protein in carcinogenesis with the in vivo back-
ground of HCV infection, present study aimed at evalu-
ation of TP53 status (genetic changes in liver samples,
cellular expression of p53 protein, anti-p53 in serum) in
patients with long-lasting (approximately 20 years)
chronic HCV infection. It was planned to find out
whether the long-lasting hepatitis C per se may be
responsible for the increased incidence of TP53 gene
mutations in genomic DNA of patients with a high
potential risk of HCC development (long-term HCV
infection, liver cirrhosis following HCV infection, 1b
genotype of HCV) but manifesting no clinical and his-
tological traits of neoplastic transformation in the liver. 
Material and methods
Liver samples. Studies were performed on archival biopsies of
liver, obtained from adult patients (n=16) with documented chron-
ic, long-lasting hepatitis C and with active replication of the virus,
confirmed serologically (all the patients were anti-HCV and
HCV RNA positive). The duration time of the infection was esti-
mated basing exlusively on the infection factor HCV (blood
transfusion, extensive operation, long hospitalization). The 16
biopsies originated from patients of the Department of Infectious
Diseases, Poznan University of Medical Sciences, in whom the
biopsies were performed in 2005-2006. All the patients were
seronegative for both HBs and HBe antigens, and for IgM antibody
against human cytomegalovirus (HCMV), against Epstein-Barr
virus (EBV) and against HIV-1 and HIV-2 by standard enzyme
immunoassays (ELISA). Other causes of liver damage (e.g. α1-antit-
rypsin deficiency, Wilson's disease, alcohol dependency) were ruled
out. All the patients had exhibited elevated serum alanine transami-
nase level (normal level below 40 IU/l) for at least 
6 months. All the patients were seropositive for antibody to HCV by
ELISA (HCV version 3.0 AXYM System, Abbott). Quantitation of
HCV RNA was conducted using AMPLICOR HCVTM test, version
2.0 (ROCHE, Mannheim, Germany) with sensitivity of 600 IU/ml.
The test was standardized against the WHO International Standard
for HCV RNA. Before liver biopsy none of the patients was sub-
jected to anti-viral therapy. Written informed consent was obtained
from each patient before liver biopsy, and approval for the study was
granted by the institution's Ethical Committee.
The control group I samples were obtained from normal livers of
serologically HCV-, HBV-, HCMV- and EBV-negative organ donors
and normal livers from tissue microarray panel (Cybrdi Inc.; Mary-
land, USA) (n=17; mean age: 58±2 years). These normal controls
were without morphological evidence of pathology and were nega-
tive controls for immunocytochemical detection of p53 protein. The
control group II consisted of the archival paraffin embedded frag-
ments of livers with hepatocellular carcinoma (HCC, n=18; mean
age: 52±4 years), among which human HCC tissue microarrays doc-
umented cases of different HCC, PCNA confirmed types (Cybrdi
Inc.; Maryland, USA). Only one patient from group II was both
HBV- and HCV-positive, in the remaining patients their serological
status related to HCV and HBV infections remained unknown. Con-
trol group II provided positive control for immunocytochemical
detection of p53 protein. Control for the studies on serum anti-p53 in
patients with chronic HCV infection included sera of 10 healthy
adult blood donors (mean age: 32±2 years). 
Liver biopsy specimens from the patients with chronic hepatitis
C and control group I were fixed in 10% buffered formalin, embed-
ded in paraffin for purposes of light microscopy. Histopathological
lesions were evaluated, following the classical H+E staining as well
as silver technique and tri-chromate technique, according to Masson
and periodic acid-Schiff with diastase pretreatment. At least 10 sec-
tions were prepared from each biopsy or from control liver frag-
ments. Each tissue specimen was evaluated basing on a numerical
scoring system for the grade of portal/periportal necroinflammation
(G1=0-4), for the grade of lobular necroinflammation (G2=0-4) and
for the stage of fibrosis (S=0-4), as proposed by Scheuer [36]. His-
tological evaluation was performed independently by two experi-
enced histopathologists (WB and JB). 
Isolation of DNA from liver. DNA for genetic studies was isolated
from liver biopsies obtained from 14 patients with chronic hepatitis
C in the course of diagnostic biopsy of the organ. The biological
material was immersed in 2 ml sterile H2O and stored in a Venosafe
tube, containing K2EDTA (final concentration of 0.1%). Samples for
further studies were frozen at the temperature of -20°C. DNA was
isolated using QIAamp DNA Blood Mini Kit (QIAGEN, Germany),
as recommended by the manufacturer. Amount and purity of the iso-
lated DNA were estimated by agarose gel electrophoresis in 0.8%
agarose gel supplemented with ethidium bromide (0.5 μg/ml). The
control involved DNA isolated from blood cells of healthy donors
(n=10; mean age: 32±2 years). 
Amplification of DNA fragments using polymerase chain
reaction (PCR). PCR reaction was performed in a Biometra ther-
mocycler in the final volume of 10 μl. The reactive mix contained
approximately 50 ng DNA, 1 μM primers, 200 μM dNTP, 2 U
Taq polymerase (DYNAzyme II DNA polymerase, 1mM spermi-
dine in the attached polymerase buffer, containing: 10mM Tris-
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HCl pH 8.8; 1.5mM MgCl2; 50mM KCl; 0.1% Triton X-100)
(FERMENTAS, Canada). The samples were subjected to prelimi-
nary denaturation for 1 min at the temperature of 94°C and, then,
subjected to 35 cycles of amplification. Every cycle consisted of
three stages, including denaturation of double stranded DNA at the
temperature of 94°C for 30 s, primer annealing to single stranded
DNA for 30 s at the temperature of 58°C and synthesis of comple-
mentary DNA at the temperature of 72°C for 1 min. In the terminal,
35th cycle the stage of complementary DNA synthesis at the temper-
ature of 72°C was extended to one minute. The amplification prod-
ucts were analysed following their electrophoretic separation in 2%
agarose gel, supplemented with ethidium bromide (0.5 µg/ml), at 
4 V/cm and their visualization under UV light. 
Single stranded conformation polymorphism (SSCP) analysis
and direct DNA sequencing for TP53 mutations. PCR-SSCP
analysis was carried out for exons 5-9 from approximately 1μg
genomic DNA of the TP53 gene, in which most frequently changes
are observed in HCC [18], using the following primers (5'→3'): 
Exon 5: CTC TGT CTC CTT CCT CTT CC and CAG CCC TGT
CGT CTC TCC
Exon 6: GCT GCT CAG ATA GCG ATG G and CCC TTA ACC
CCT CCT CCC
Exon 7: TGC TTG CCA CAG GTC TCC and CAG ACG AGG
CCA GTG TGC
Exon 8: GAC CTG ATT TCC TTA CTG CC and GAA TCT GAG
GCA TAA CTG C
Exon 9: CAG GGA GCA CTA AGC GAG and TCC ACT TGA
TAA GAG GTC CC
The primers were designed using Primer Selekt, DNAstar software.
They were produced by the Institute of Biochemistry and Biophysics
(IBB) PAN, Warszawa, Poland. PCR product in the volume of 10 μl
was mixed with 12.5 μl formamide (chemical denaturation) and 
2.5 μl staining buffer for SSCP (final concentrations of components:
TBE-0.25x, 2% Ficol-400; 0.01% bromophenol blue and 0.01%
xylene cyanole FF). Subsequently, the DNA-containing mixture was
subjected to thermal denaturation at the temperature of 95°C for 10
min and cooled in ice. The next stage included electrophoretic sepa-
ration in 10% polyacrylamide gel (PAA) in 0.5% TBE buffer, at 180V
for approximately 12 hours. The separated DNA bands were stained
with silver salts. For this purpose the DNA-containing PAA gel was
incubated with slight shaking, passing it consecutively through 10%
ehanol solutions for 15 min and 1% HNO3 for 10 min. Then, it was
stained with 0.2% AgNO3 solution and 0.1% formaldehyde for 
30 min and developed using 3% Na2CO3 and 0.05% formaldehyde
solution. The reaction was blocked using 10% acetic acid for 15 min.
At the next stage PAA gel was incubated in 4% glycerol for 20 min
and dried at the temperature of 75°C. Between the consecutive solu-
tions, the gel was rinsed with high amounts of MiliQ water.
Direct PCR sequencing. DNA fragments which demonstrated dis-
tinct migration from that in control samples were amplified by PCR
using the same primers. Products of PCR reaction were purified
using QIAquick PCR Purification KIT (QIAGEN, Germany) as
suggested by the manufacturer and were subjected to automated
sequencing. The studies were performed in the Faculty Laboratory
of Molecular Biology Techniques, Adam Mickiewicz University in
Poznañ. Sequencing analysis took advantage of the 3130x Genetic
Analyzer (Applied Biosystem) using Big Dye Terminator v 31 cycle
sequencing kit. Results of sequencing were analyzed using Chromas
software. Comparison of nucleotide sequences and translation of
nucleotide sequences into amino acid sequences were performed
using BLAST software (http://www.ncbi.nlm.nih.gov/BLAST). 
Concentration of serum autoantibodies reactive with p53 (anti-
p53) in patients' blood. Anti-p53 were estimated in serum of 16
patients using p53 ELISAPLUS (Autoantibody Kit, CalbiochemR).
The control included 10 sera obtained from healthy donors. The
assay was interpreted by determining the relative p53-autoimmune
index, which was calculated as follows:
ABS450(sample) – ABS450 (cut-off)/ABS450(calibrator) –
ABS450(cut-off) = p53 Autoimmune Index
Cut-off for the obtained curve at the absorbance level of 0.15
(ABS450) amounted to 0.125 U/μl. When a dilution was taken into
account, the cut-off value in tested sera of patients with hepatitis C
and of control subjects amounted to 12.5 U/μl. 
p53 protein immunocytochemistry. For immunocytochemistry,
5 μm thick sections were cut and mounted onto SuperFrost/Plus
microscope slides. Mouse anti-human monoclonal antibodies were
employed, directed against p53 protein (ready-to-use) (clone DO-7;
DAKO, Glostrup, Denmark), which recognized the epitop located
within amino acids 35-45 of the N-terminus of wild and mutant types
of the p53 protein. After deparaffination and rehydration of prepara-
tions in xylene and a row of alcohols of a decreasing concentration
(2x100%, 90%, 85%, 80%, 70%), they were washed in tap water 
(10 min), activity of endogenous peroxidase was blocked using 1%
H2O2 (30 min). Subsequent washing in a distilled water was followed
by incubation of the preparations in a normal goat serum (1:20,
DAKO) (30 min). Then, the sections were treated with primary MAb
at night at 4°C and for 1 h at room temperature. After washing in
phosphate-buffered saline (PBS) 3×3 min, the sections were incubat-
ed with the secondary biotinylated link anti-mouse and anti-rabbit
IgG (DAKO) (20 min) and with the streptavidin-biotin-peroxidase
complex (LSAB2, DAKO) (20 min). They were sequentially washed
in PBS 3×3 min, incubated (7 min) with the HRP substrate, 0.05%
3,3-diaminobenzidine tetrahydrochloride (DAB) (DAKO) in 0.05 M
Tris-HCl buffer, pH 7.6, supplemented with 0.001% H2O2, washed in
tap water and in distilled water (2x10 min), dehydrated in a row of
alcohols of an increasing concentration (70%, 85%, 90%, 95%,
2x100%), and equilibrated with xylene. The preparations were sealed
under coverslips in the Canada balsam. Selected preparations were
counterstained with hematoxylin (2 min). The studies followed the
classical ABC technique [37] with microwave-oven pretreatment for
antigen retrieval. Positive reaction manifested, in at least three
sequential sections, as a dark brown or black precipitate in the cell
nucleus and/or cytoplasm. Control reactions were based on substitut-
ing specific antibodies with normal sera of the respective species in
0.05 M Tris-HCl, pH 7.6, supplemented with 0.1% BSA and 15 mM
sodium azide (negative control). 
Semiquantitative evaluation of the results and statistics. The con-
tent of p53 protein in liver biopsies were calculated by the semiquan-
titative technique and reported as follows: 0=0% positive cells; 1=
individual positive cells (<10%); 2=10-25% positive cells; 3≥26-50%
positive cells; 4≥51-75% positive cells, according to [38], evaluating
10 microscopic fields at magnification of 400x. The final result rep-
resented mean score for the 10 fields. Expression of p53 protein was
evaluated only in hepatocytes (cell nuclei and/or cytoplasm). All the
preparations were examined under an OLYMPUS B-2 light micro-
scope. The descriptive statistics included calculation of mean, medi-
an values, standard deviation and standard error of the mean (SEM)
for quantitative traits. In order to determine statistical significance of
variations in the expression intensity of the p53 protein, we first cal-
culated the mean values of staining scores for liver biopsy groups. In
comparison of quantitative traits the Mann-Whitney's U test for was
used for non-parametric independent data. Correlations between data
rows were determined employing Spearman's rank correlation index.
Probability values less than 0.05 were considered significant.
Results
At the time of biopsy the mean age of patients (10
men and 6 women) was 41±4 years (range: 19 to 65
years). At the time of liver biopsy, the mean duration
of HCV infection was 19±2 years. The majority
(69%) of the patients included in our study were
infected by HCV genotype 1b (Table 1).
p53 DNA analysis
Mutational analysis by PCR-SSCP showed two from 14
examined HCV-infected liver samples with aberrant
migration pattern indicative of genomic aberration and
only in exon 7. Examples of results obtained in DNA sin-
gle strand conformational polymorphism DNA (SSCP)
related to exon 7 of TP53 are shown in Fig. 1. Differ-
ences in migration of single strand DNA fragments are
marked with arrows. The separation in 10% polyacry-
lamide gel was repeated as shown in the two panels.
Direct PCR sequencing analysis was performed in the
samples with aberrant SSCP bands to characterize the
genetic aberration. In the patient No. 10 a C to T substi-
tution was demonstrated in the first position of codon
250 (CCC→TCC), resulting in interchange of proline to
serine. In the patient No. 11 a substitution of C to G was
demonstrated in position 13274 of the intron 6 (Table 1). 
Anti-p53
All blood samples in HCV-infected patients tested for
the presence of anti-p53 demonstrated values below
the threshold level (Table 1). In the curve of the test at
the absorbance of 0.15 the cut-off value amounted to
0.125 U/l. Taking into account the dilution, the final
cut-off value was 12.5 U/μl. Mean value of p53 anti-
bodies in HCV-infected patients was 7.34±0.37 U/μl
and in control group was 6.80±0.42. No significant
difference of studied serum p53 antibodies was esti-
mated between the HCV-infected patients and control
patients (p=0.28) (data not shown). 
p53 immunocytochemistry
The total immunocytochemical detectability of p53 pro-
tein amounted to 8/16 (50%) of tested liver biopsies in
patients with chronic hepatitis C. There were 6 samples
which showed positive nuclear p53 expression but in
less than 10% of the cells, one sample which showed 10-
25% p53-positive cells and one sample which showed
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Table 1. p53 protein immunocytochemical expression, TP53 mutation and anti-p53 detected in each patient in relation to the clinical and
histopathological features of HCV-infected patients
G1 – portal/periportal inflammatory activity (grading); G2-grading in lobules; S-advancement in fibrosis (staging); 1score according to [36]; 2Score: 0=0%
cells; 1=individual positive cells (<10%); 2=10-25% positive cells; 3=26-50% positive cells; 4=51-75% positive cells according to [38]; * – nuclear+cyto-
plasmic expression in hepatocytes; nt – not tested; pos. – position
>50% p53-positive cells (Fig. 2A). In two cases cyto-
plasmic plus nuclear localization of p53 was observed in
chronically HCV-infected livers (cases no 11 and 16)
(Table 1). In the control group I no p53 protein could be
detected in any of examined samples (Fig. 2B). In the
material of liver with HCC (control group II) presence of
individual or very numerous p53-immunoreactive cell
nuclei was disclosed in 11/18 patients (61%) (Fig. 2C
and Fig. 2D). In two cases of HCC cytoplasmic reaction
for the protein prevailed (Fig. 2D). 
Correlations between expression of p53 protein 
in HCV infected patients and selected clinical data
Positive Spearman's correlations could be disclosed
between tissue expression of p53 protein and intensity
of inflammatory lesions (grading) both in portal
spaces (G1) (r=0.548; p=0.03), and in hepatic lobuli
(G2) (r=0.551; p=0.03) as well as between intensity of
p53 protein expression and staging (r=0.705;
p=0.002). A negative Spearman's correlation was dis-
closed between tissue expression of p53 protein and
duration of the infection (r=-0.570; p=0.04) in patients
with chronic hepatitis C. No correlation could be
detected between expression of p53 and age of the
patients (r=0.368; p=0.16). 
Characteristics of patients with chronic 
hepatitis C and TP53 aberrations
In the patient No. 10 (infected by HCV genotype 1b),
with C→T transition in position 1 of the codon 250
(exon 7) (CCC→TCC; interchange of proline to serine),
the most pronounced nuclear expression of p53 protein
was noted (above 50% of cells) among the 16 examined
patients by immunohistochemistry. In histopathological
examination the patient manifested traits of liver cirrho-
sis and a significant grading in portal spaces. In the
patient, duration of HCV infection could not be deter-
mined. Despite the documented point mutation, no ele-
vated levels of anti-p53 antibodies could be detected in
serum of the patient. The second patient, No. 11 (infect-
ed by HCV genotype 3a) in molecular tests demonstrat-
ed C→G transversion in position 13274 of the intron 
6 of TP53, and in the immunocytochemical examination
positive nuclear and cytoplasmic location of p53 was
demonstrated but only in few (below 10%) hepatocytes.
In the patient a moderate grading (2 points) and staging
(2 points) was disclosed and duration of the infection
reached 10 years. No elevated titers of anti-p53 antibod-
ies were demonstrated. 
Discussion
Multiple reports have appeared worldwide which
described genetic alterations in TP53 also in codons
other than codon 249 of the gene (e.g., codons 136,
156, 157, 213) and most of them involved missense
point mutations [8,18,19,29,30]. Mutations of TP53
with interchange of a single amino acid were identified
in over 100 different codons [33]. Aberrations were
also observed which affected introns of TP53 [30]. In
HCC described by European authors mutation in the
codon 249 was detected in a single case [19]. Few
studies have suggested that losses and gains of chro-
mosome regions may differ in HCCs caused by HBV
as compared to HCV infection [39]. Few studies have
dealt with incidence of genetic aberrations in TP53 in
patients with non-neoplastic liver pathology or with
risk factors prompting development of HCC (e.g.
chronic viral infections) or the reports relate to select-
ed exons of TP53 [32,34,35,40]. No mutations in the
codon 249 were detected in North American patients
with chronic hepatitis and/or liver cirrhosis as com-
pared to 5/6 positive samples of non-neoplastic liver
from Mozambican patients (HBV infection and AFB1
exposure) [40]. Studies on TP53 alterations in normal
liver samples demonstrated a linear relationship
between incidence of mutations in the codon 249 and
the extent of exposure to AFB1 [35]. Akyol et al. in 
21 different pathological entities of non-tumoral liver,
demonstrated overexpression of p53 protein in 35%
specimens, significantly more frequent in patients with
steatohepatitis [32]. Studies in non-tumorous tissues of
patients with Wilson's disease and hemochromatosis
documented higher frequency of genetic aberrations
(transversions and transitions) in both codons 249 and
250 of TP53 in the patients, as compared to healthy
controls [34]. Examination of genetic lesions in pres-
ent study pertained the exons 5-9 of TP53, in which
gene aberrations were described most frequently
[18,19,23,26,27,38]. Genetic alterations and p53 protein
expression were examined at the tissue level and 
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Fig 1. Examples of results obtained in PCR-SSCP analysis of
TP53 gene exon 7 in control (C) samples and HCV-infected liver
samples (patients No 6-14). Lane M shows electrophoretic pattern
of size marker (pUC). The arrows indicate changes in migration of
individual pre-denatured PCR products in 10% polyacrylamide gel
(they indicate the genetic TP53 changes in liver samples No 10
and 11). The separation in polyacrylamide gel was repeated. Sam-
ple identification corresponds to numbers of patients in Table 1. 
presence of anti-p53 antibodies was looked for in sera of
the patients. In the present study alterations in TP53
nucleotide sequence were documented in two patients
(in the codon 250 and intron 6). In the first patients a
transition of C→T was detected in position 1 of the
codon 250 (exon 7) (CCC→TCC) which caused substi-
tution of proline by serine and presence of p53 protein in
cell nuclei of numerous hepatocytes. The patient mani-
fested traits of liver cirrhosis and was infected with HCV
genotype type 1b. The other patient in molecular studies
demonstrated transversion C→G in position 13274 of
the intron 6 in TP53 gene while immunocytochemical
examination detected p53 localization in cell nuclei and
cytoplasm of few hepatocytes. C:G to T:C transversions
and C:G to T:A transitions were demonstrated also in the
codon 250 in a patient with Wilson's disease [34]. It
seemed significant that the mutations were detected at
the stage which preceded a potential neoplastic process,
allowing to undertake appropriate therapeutic proce-
dures. Correlations were described between specific
TP53 mutations and less favourable prognosis or
response to therapy [33]. A significantly abbreviated sur-
vival characterized patients with HCC and with TP53
mutations [8]. Studies on clinical significance of detec-
tion of so variable alterations in TP53 have indicated that
a heterogenous cellular response to carcinogenic factors
(including viral infections) is related to both inherent
ability of individual TP53 gene mutants to inhibit func-
tion of wild type p53 and to the status of the remaining
allele of TP53 [33]. However, an enhanced risk for
developing HCC exists when the active HCV infection
(present in all patients examined in this study) is accom-
panied by mutations in TP53 [28]. 
Examination of p53 protein alone in other non-neo-
plastic patients with HCV infection (but still free of
HCC) using an immunoluminometric technique have
demonstrated overexpression of p53 in almost 18% of
the patients [4]. In this study, application of ABC tech-
nique has confirmed both nuclear and cytoplasmic
localization of p53 protein. However, in most of the
patients the expression has been low or has been absent.
In the examined material, the definitely highest propor-
tion (above 50%) of cells with positive immunocyto-
chemical reaction in cell nuclei of hepatocytes has been
demonstrated in the patient with mutation in the codon
250 of TP53. This is consistent with the general obser-
vation that mutations of TP53 often stabilize the protein,
leading to higher steady-state p53 levels than in wild
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Fig. 2. The slide shows fragment of chronic HCV-infected patient's liver and TP53 mutation (Patient No. 10) with immunocytochemical
localization of p53 protein in hepatocyte nuclei (A), normal liver (control group I) with no positive staining of p53 protein in hepatocytes
(B), immunocytochemical localization of p53 protein in many cell nuclei in HCC patient (C); and HCC patient with p53-positive cell's
cytoplasm and nuclei (D). (Strept)avidin-biotin peroxidase complex (ABC) method. Hematoxylin counterstain (original magnification
x400).
type cells and that this can be detected by immunocyto-
chemical techniques [16]. It is also assumed that protein
of nuclear localization has lost its transcriptional activi-
ty [17]. However, it has been shown that not all muta-
tions stabilize p53 and, thus, application of exclusively
immunocytochemical techniques in studies of TP53
expression may underestimate incidence of mutations in
tumors with deletions, frameshift or nonsense TP53
mutations [17,41]. On the other hand, in present study
mutations in TP53 have been detected not always in the
cases with expression of the protein in cell nuclei. Pres-
ence of p53-immunopositive cells in the absence of
sequence mutations was observed also by other authors
[24,30]. Overexpression of p53 protein, usually associ-
ated with point mutations in TP53 gene, was detected in
almost half of HCC cases studied in Europe [20]. Other
European studies on non-neoplastic diseases of the liver
(liver cirrhosis due to HBV and HCV infections), con-
ducted by Koskinas et al., have failed to demonstrate
expression of the protein in the tissue [31]. 
In this study we have demonstrated also a cytoplas-
mic localization of p53 protein in individual cells both
in the patient with alteration in the intron 6 of TP53 and
in the patient with no detectable genetic alterations in
exons 5-9 of TP53 but with morphological traits of liver
cirrhosis. In two our cases of HCC cytoplasmic reaction
for the protein (control group II) was observed. Multiple
studies were devoted to cellular localization of both the
wild and the mutated p53 protein [15,42-44]. Various
types of human tumors, including HCC, have demon-
strated abnormal p53 cytoplasmic localization, and this
is associated with tumour metastasis and poor prognosis
[43]. p53 protein localized in the cytoplasm is thought
to be less responsive to signals that would normally
induce its nuclear retention [42]. Cytoplasmic seques-
tration of p53 in tumor cells is linked to a poor long-
term patient survival and may be substantial fraction of
tumors that do not have mutated p53 [45]. In none of the
patients examined in this study have elevated serum
titers of anti-p53 been detected despite presence of
TP53 mutations and/or immunocytochemical detection
of p53 protein in livers of the patients. This is consistent
with observations of Readle et al. on a large group of
patients with HCV-related HCC and non-neoplastic
lesions [46]. The authors and several other investigators
state that presence of anti-p53 is highly specific for the
already developed tumor and that incidence of the anti-
bodies varies between 7 and 20% HCC [46-48]. Other
studies on prognostic significance of anti-p53 antibod-
ies in diagnosis of malignant tumors, including HCC,
have shown that just in HCC and in breast cancer ele-
vated serum anti-p53 signify less advantageous progno-
sis as to survival of the patients (analysis of Kaplan-
Meier). Diagnostic sensitivity of the marker increases
when it is applied in line with conventional tumor mark-
ers [49].
It is difficult to interpret the negative correlation
between expression of p53 protein in our patients and
duration of the infection. The positive correlations
between expression of mutated p53 and of inflammato-
ry lesions (grading) and advancement of liver fibrosis
(staging) in our HCV-infected patients prove that histo-
logical lesions provide a much more reliable marker of
the disease progression than duration of the infection
(not always reliably documented). The positive relation-
ships between p53 expression and grading, both in
cases of non-neoplastic liver damage [32] and in already
developed HCC have been described by other authors
[20,31]. However, other studies on HCC have failed to
document correlations between p53 expression and age
or grading [21]. As indicated by long-term studies on
patients with mutations of TP53, who did not develop
HCC in the course of 5 years, biological significance of
genetic alterations in TP53, detected in non-neoplastic
patients remains probably distinct than that in patients
with HCC [26], but it seems important to cover the
patients with point mutations in TP53 and with overex-
pression of tissue p53 with a particular care and to treat
them as a group carrying the risk of development of
HCC and/or of other tumors.
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